|
1
|
Fisher B, Anderson S, Tan-Chiu E, Wolmark
N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N,
Merajver S, et al: Tamoxifen and chemotherapy for axillary
node-negative, estrogen receptor-negative breast cancer: Findings
from National Surgical Adjuvant Breast and Bowel Project B-23. J
Clin Oncol. 19:931–942. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colleoni M, Gelber S, Goldhirsch A, Aebi
S, Castiglione-Gertsch M, Price KN, Coates AS and Gelber RD;
International Breast Cancer Study Group: Tamoxifen after adjuvant
chemotherapy for premenopausal women with lymph node-positive
breast cancer: International Breast Cancer Study Group Trial 13-93.
J Clin Oncol. 24:1332–1341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merglen A, Verkooijen HM, Fioretta G,
Neyroud-Caspar I, Vinh-Hung V, Vlastos G, Chappuis PO, Castiglione
M, Rapiti E and Bouchardy C: Hormonal therapy for oestrogen
receptor-negative breast cancer is associated with higher
disease-specific mortality. Ann Oncol. 20:857–861. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huszno J and Nowara E: Current therapeutic
strategies of anti-HER2 treatment in advanced breast cancer
patients. Contemp Oncol (Pozn). 20:1–7. 2016.
|
|
5
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Invasive Breast Cancer Version 1.2016, NCCN
Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.
14:324–354. 2016. View Article : Google Scholar
|
|
8
|
Cortes J, O'Shaughnessy J, Loesch D, Blum
JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V,
Delozier T, et al EMBRACE (Eisai Metastatic Breast Cancer Study
Assessing Physician's Choice Versus E7389) investigators: Eribulin
mono-therapy versus treatment of physician's choice in patients
with metastatic breast cancer (EMBRACE): A phase 3 open-label
randomised study. Lancet. 377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Denkert C, Liedtke C, Tutt A and von
Minckwitz G: Molecular alterations in triple-negative breast
cancer-the road to new treatment strategies. Lancet. 389:2430–2442.
2017. View Article : Google Scholar
|
|
10
|
Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB,
Jung KH, Gong GY, Kim MJ, Son BH and Ahn SH: Impact of
triple-negative breast cancer phenotype on prognosis in patients
with stage I breast cancer. J Breast Cancer. 15:197–202. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas N; Cancer Genome Atlas
Network: Comprehensive molecular portraits of human breast tumours.
Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ,
et al: The somatic mutation profiles of 2,433 breast cancers
refines their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012.PubMed/NCBI
|
|
15
|
O'Shaughnessy J, Osborne C, Pippen JE,
Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C:
Iniparib plus chemotherapy in metastatic triple-negative breast
cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tutt A, Robson M, Garber JE, Domchek SM,
Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler
RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer:
A proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamaguchi N, Ito T, Azuma S, Ito E, Honma
R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Watanabe S, et
al: Constitutive activation of nuclear factor-kappaB is
preferentially involved in the proliferation of basal-like subtype
breast cancer cell lines. Cancer Sci. 100:1668–1674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu XF, Xiang L, Zhang Y, Becker KG, Bera
TK and Pastan I: CAPC negatively regulates NF-κB activation and
suppresses tumor growth and metastasis. Oncogene. 31:1673–1682.
2012. View Article : Google Scholar
|
|
19
|
Kurebayashi J, Kurosumi M and Sonoo H: A
new human breast cancer cell line, KPL-3C, secretes parathyroid
hormone-related protein and produces tumours associated with
microcalcifications in nude mice. Br J Cancer. 74:200–207. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Komatsu M, Yoshimaru T, Matsuo T, Kiyotani
K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto
S, et al: Molecular features of triple negative breast cancer cells
by genome-wide gene expression profiling analysis. Int J Oncol.
42:478–506. 2013. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Kim JW, Akiyama M, Park JH, Lin ML, Shimo
A, Ueki T, Daigo Y, Tsunoda T, Nishidate T, Nakamura Y, et al:
Activation of an estrogen/estrogen receptor signaling by BIG3
through its inhibitory effect on nuclear transport of PHB2/REA in
breast cancer. Cancer Sci. 100:1468–1478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JH, Lin ML, Nishidate T, Nakamura Y
and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein
kinase, a putative cancer/testis antigen with an oncogenic activity
in breast cancer. Cancer Res. 66:9186–9195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamimae S, Yamamoto E, Kai M, Niinuma T,
Yamano HO, Nojima M, Yoshikawa K, Kimura T, Takagi R, Harada E, et
al: Epigenetic silencing of NTSR1 is associated with lateral and
noninvasive growth of colorectal tumors. Oncotarget. 6:29975–29990.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ng FW, Nguyen M, Kwan T, Branton PE,
Nicholson DW, Cromlish JA and Shore GC: p28 Bap31, a Bcl-2/Bcl-XL-
and procaspase-8-associated protein in the endoplasmic reticulum. J
Cell Biol. 139:327–338. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Annaert WG, Becker B, Kistner U, Reth M
and Jahn R: Export of cellubrevin from the endoplasmic reticulum is
controlled by BAP31. J Cell Biol. 139:1397–1410. 1997. View Article : Google Scholar
|
|
27
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
|
|
28
|
Huang W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar :
|
|
29
|
Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ,
Liu C, Li JL, Ding YQ and Li JM: A five-gene signature as a
potential predictor of metastasis and survival in colorectal
cancer. J Pathol. 220:475–489. 2010.PubMed/NCBI
|
|
30
|
Yoshimaru T, Komatsu M, Matsuo T, Chen YA,
Murakami Y, Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi
R, et al: Targeting BIG3-PHB2 interaction to overcome tamoxifen
resistance in breast cancer cells. Nat Commun. 4:24432013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kajiura K, Masuda K, Naruto T, Kohmoto T,
Watabnabe M, Tsuboi M, Takizawa H, Kondo K, Tangoku A and Imoto I:
Frequent silencing of the candidate tumor suppressor TRIM58 by
promoter methylation in early-stage lung adenocarcinoma.
Oncotarget. 8:2890–2905. 2017. View Article : Google Scholar :
|
|
32
|
Locke WJ and Clark SJ: Epigenome
remodelling in breast cancer: Insights from an early in vitro model
of carcinogenesis. Breast Cancer Res. 14:2152012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang X: miRDB: A microRNA target
prediction and functional annotation database with a wiki
interface. RNA. 14:1012–1017. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peña-Chilet M, Martínez MT, Pérez-Fidalgo
JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E,
Martinez-Delgado B, Eroles P, Climent J, et al: MicroRNA profile in
very young women with breast cancer. BMC Cancer. 14:5292014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nguyen HT, Li C, Lin Z, Zhuang Y,
Flemington EK, Burow ME, Lin YI and Shan B: The microRNA expression
associated with morphogenesis of breast cancer cells in
three-dimensional organotypic culture. Oncol Rep. 28:117–126.
2012.PubMed/NCBI
|
|
36
|
Yan J and Aldrich RW: BK potassium channel
modulation by leucine-rich repeat-containing proteins. Proc Natl
Acad Sci USA. 109:7917–7922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carvalho S, Oliveira T, Bartels MF,
Miyoshi E, Pierce M, Taniguchi N, Carneiro F, Seruca R, Reis CA,
Strahl S, et al: O-mannosylation and N-glycosylation: Two
coordinated mechanisms regulating the tumour suppressor functions
of E-cadherin in cancer. Oncotarget. 7:65231–65246. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Couldrey C and Green JE: Metastases: The
glycan connection. Breast Cancer Res. 2:321–323. 2000. View Article : Google Scholar
|
|
39
|
Dall'Olio F, Malagolini N, Trinchera M and
Chiricolo M: Mechanisms of cancer-associated glycosylation changes.
Front Biosci (Landmark Ed). 17:670–699. 2012. View Article : Google Scholar
|
|
40
|
Pinho SS and Reis CA: Glycosylation in
cancer: Mechanisms and clinical implications. Nat Rev Cancer.
15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al American Society of Clinical Oncology; College
of American Pathologists: Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American Society
of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sobin L, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumors. John Wiley & Sons, Inc;
Hoboken, NJ: 2010
|
